Trial Profile
A prospective, multicenter, double-blind with in-house blinding, randomized, comparative study to evaluate the efficacy, safety, and tolerability of ertapenem sodium versus piperacillin/tazobactam in the treatment of complicated intra-abdominal infections in hospitalized adults
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Ertapenem (Primary) ; Piperacillin/tazobactam
- Indications Bacterial infections; Intra-abdominal infections
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 21 Nov 2006 New trial record.